Inflammatory Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Inflammatory breast cancer is a
rapidly progressing and aggressive form of breast cancer characterized by the
infiltration of cancer cells into the skin and lymph vessels of the breast.
Unlike many other breast cancers, it often lacks a distinct tumor or lump that
can be palpated within the breast. Early symptoms of inflammatory breast cancer
may manifest as persistent itching and a rash or small irritation resembling an
insect bite. The affected breast typically becomes red, swollen, and warm,
accompanied by the dilation of pores on the breast skin, which can give it a
pitted appearance similar to an orange peel. Additionally, changes in the
nipple, such as inversion, flattening, or dimpling, may occur. There are
several established risk factors associated with inflammatory breast cancer.
Reproductive factors play a significant role, with a higher risk observed in
women who experience early menarche and give birth to their first child at a
younger age. Inflammatory breast cancer is categorized into either stage 3B,
3C, or stage 4, each with distinct characteristics:
·
Stage 3B involves the spread of cancer into
nearby tissues, such as the skin of the breast and the underlying chest muscle,
potentially extending to lymph nodes in the armpit.
·
Stage 3C signifies the presence of cancer in
lymph nodes located in the armpit or below the breastbone, either above or
below the collarbone.
·
Stage 4 indicates that the cancer has extended
beyond the breast and nearby lymph nodes.
The
minimum criteria for diagnosing inflammatory breast cancer include the
following:
1. The rapid
onset of symptoms, including redness (erythema), swelling (edema), a peau
d'orange texture (ridged or pitted skin), and abnormal warmth in the breast,
with or without a palpable lump.
2. The
symptoms have been present for less than six months.
3. The
redness (erythema) affects at least one-third of the breast.
4. Initial
biopsy samples from the affected breast confirm the presence of invasive
carcinoma.
Treatment
for inflammatory breast cancer typically includes surgery, radiation therapy,
chemotherapy, and hormone treatments.
·
In the United States, there are an estimated
3.1 cases of inflammatory breast cancer per 100,000 women, which is more
commonly diagnosed in women under 40.
Thelansis’s “Inflammatory Breast
Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2022 To 2032" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Inflammatory Breast Cancer
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Inflammatory Breast Cancer across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Inflammatory Breast Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment